Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic, Randomized Controlled Trial
Start Date
5/26/2021
Completion Date
3/1/2027
Summary
Two arm, pragmatic, randomized controlled multicenter Phase III noninferiority trial evaluating the efficacy of standard pain management without NSAIDs (Group 1) vs. standard pain management plus up to 6 weeks of NSAIDs (Group 2) in the treatment of tibial shaft fractures.
Detailed Description
The proposed study is a two arm, pragmatic, randomized controlled multicenter Phase III noninferiority trial. We will randomize patients with diaphyseal tibia fractures treated with intramedullary (IM) nail into two treatment arms. The control group will receive standard pain management with no NSAIDs. The treatment intervention group will receive standard pain management plus up to six weeks of NSAIDs (3 weeks of prescribed medication followed by 3 weeks of medication PRN). Our hypothesis is that pain management using up to 6 weeks of NSAIDs will result in improved pain control and lower opioid consumption but demonstrate non-inferior levels of complications compared to standard of care pain management. The aim of the study is to: Specific Aim: Evaluate the effect of standard pain management without NSAIDs (Group 1) vs. standard pain management plus up to 6 weeks of NSAIDs (Group 2) in the treatment of tibial shaft fractures. Primary Hypothesis: When compared to patients who received standard of care pain management, patients treated with up to 6 weeks of NSAIDs will have noninferior rates of surgery for nonunion at one year. Secondary Hypotheses: When compared to patients who received standard of care pain management without NSAIDs, patients treated with up to 6 weeks of NSAIDs will benefit from (1) reduced opioid utilization; (2) reduced levels of persistent pain; (3) reduced pain interference; (4) improved functional outcomes; (5) noninferior rates of analgesic treatment related side effects; and (6) noninferior rates of radiographic union.
Eligibility Criteria
Age Range: 18 years to 80 years
Interventions
600 mg Ibuprofen
Conditions
Locations
Eskenazi Hospital
Indianapolis, Indiana 46202
United States
Indiana University-Methodist
Indianapolis, Indiana 46202
United States
University of Maryland R Adams Cowley Shock Trauma Center
Baltimore, Maryland 21201
United States
Harvard Medical Center
Cambridge, Massachusetts 02138
United States
Hennepin Health
Minneapolis, Minnesota 55487
United States
University of Mississippi
Jackson, Mississippi 39216
United States
The MetroHealth System
Cleveland, Ohio 44109
United States
Allegheny General Hospital
Pittsburgh, Pennsylvania 15212
United States
Vanderbilt Medical Center
Nashville, Tennessee 37203
United States
University of Texas Health Science Center - Houston
Houston, Texas 77030
United States
University of Utah
Salt Lake City, Utah 84108
United States
Inova Fairfax Hospital
Falls Church, Virginia 22042
United States
University of Wisconsin
Madison, Wisconsin 53705
United States
University of Calgary, Foothills Medical Centre
Calgary, Alberta
Canada